CTOs on the Move


 
GlobalMed Inc. is a Trenton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.globalmedinc.com
  • 155 N Murray St PO Box 340 Stn Main
    Trenton, ON CAN K8V 5R5
  • Phone: 613.394.9844

Executives

Name Title Contact Details

Similar Companies

EAR TECHNOLOGY

EAR TECHNOLOGY Corp. is a Johnson City, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Velano Vascular

Velano Vascular aims to improve the hospital experience by reducing the pain, anxiety, and inefficiencies of blood draws.

Milestone Scientific

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone`s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone`s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections.

Trimline Medical Products Corp

Trimline Medical Products Corp is a Branchburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ValenTx

ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.